

METHODS IN MOLECULAR BIOLOGY

Series Editor
John M. Walker
School of Life and Medical Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:
<http://www.springer.com/series/7651>

Targeted Drug Delivery

Methods and Protocols

Edited by

Rachael W. Sirianni

Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA; Barrow Neurological Institute, Phoenix, AZ, USA

Bahareh Behkam

Department of Mechanical Engineering, Virginia Tech, Blacksburg, VA, USA; School of Biomedical Engineering and Sciences, Virginia Tech, Blacksburg, VA, USA; Macromolecules Innovation Institute, Virginia Tech, Blacksburg, VA, USA

Editors

Rachael W. Sirianni
Vivian L. Smith Department of Neurosurgery
University of Texas Health Science
Center at Houston
Houston, TX, USA

Barrow Neurological Institute
Phoenix, AZ, USA

Bahareh Behkam
Department of Mechanical Engineering
Virginia Tech
Blacksburg, VA, USA

School of Biomedical Engineering and Sciences
Virginia Tech
Blacksburg, VA, USA

Macromolecules Innovation Institute
Virginia Tech
Blacksburg, VA, USA

ISSN 1064-3745

ISSN 1940-6029 (electronic)

Methods in Molecular Biology

ISBN 978-1-4939-8659-0

ISBN 978-1-4939-8661-3 (eBook)

<https://doi.org/10.1007/978-1-4939-8661-3>

Library of Congress Control Number: 2018948358

© Springer Science+Business Media, LLC, part of Springer Nature 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Humana Press imprint is published by the registered company Springer Science+Business Media, LLC part of Springer Nature.

The registered company address is: 233 Spring Street, New York, NY 10013, U.S.A.

Preface

Our species has long recognized that *where* and *how* a drug is applied to the body will alter its biological potency. Inhalation of nicotine produces mild and transient euphoria; ingestion of the same substance is lethal. An antibiotic washed over the surface of the skin may become ineffective quickly; the same substance administered as a systemic therapy, or released slowly from a carefully prepared topical bandage, can halt a life-threatening infection.

Modern approaches to drug delivery originated in a happenstance experiment performed by the great angiogenesis researcher Judah Folkman. While utilizing Silastic® (silicone rubber) tubing as an arterio-venous shunt in rabbits, Folkman and colleagues noticed that exposing the external surface of the tubing to anesthetic gases produced sedation [1]. Perhaps most significantly, the silastic tubing could be implanted, and altering the thickness of the tubing changed the rate at which molecules were transported through the material. Several years later, a scientist by the name of Robert Langer would conduct postdoctoral research in Folkman's laboratory. In 1976, Folkman and Langer published the first report utilizing polymeric biomaterials to deliver and control the action of macromolecules [2]. Thus the field of drug delivery was born.

From these basic beginnings, drug delivery has become an essential consideration in fields ranging from oncology to infectious disease, endocrinology, and reproductive medicine. Drug-loaded biomaterials are integrated into many kinds of medical practice, with the greatest clinical successes observed for implants and coatings that locally release their active agents. More recent innovations highlight the potential of miniaturizing these biomaterials to serve as circulating or mobile carriers for active agents. Our challenge as scientists invested in the field of nanocarrier drug delivery has become even greater and focused across an even smaller length scale: can we design therapeutic approaches that will redirect drug distribution to target tissue and cellular compartments? Such targeting will enhance drug potency to treat disease while reducing systemic exposure and toxicity.

In this volume on *Targeted Drug Delivery*, we will address important methods that enable therapeutic molecules to be targeted for site-specific delivery. In Part I, we will describe approaches to formulate biologically derived and synthetic nanocarriers. Part II will overview diverse strategies to facilitate nanocarrier targeting to specific cells and tissues. In Part III, we will cover select methods for evaluating delivery and efficacy of these new classes of agents.

As is often observed in the field of bioengineering, these methods will integrate chemistry, physics, and biology to solve important medical problems. It is our hope that this volume will serve as a valuable resource to understand the diversity of scientific methods available to achieve targeted drug delivery.

Houston, TX, USA
Blacksburg, VA, USA

Rachael W. Sirianni
Bahareh Behkam

References

1. Folkman J, Long DM (1964) The use of silicone rubber as a carrier for prolonged drug therapy. *J Surg Res* 4(3):139–142
2. Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromolecules. *Nature* 263:797–800

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>ix</i>

PART I DRUG CARRIER DESIGN

1 Synthesis of Cationic Polymer Libraries for Gene Delivery Using Diglycidyl Ethers	3
<i>Jacob Elmer, Thrimoorthy Potta, and Kaushal Rege</i>	
2 Generation of Ultra-Small PLGA Nanoparticles by Sequential Centrifugation	17
<i>Xingwang Wu, Jiangbing Zhou, and Toral R. Patel</i>	
3 Construction of Bacteria-Based Cargo Carriers for Targeted Cancer Therapy	25
<i>Mahama A. Traore, Ali Sahari, and Bahareh Behkam</i>	
4 Production of Extracellular Vesicles Loaded with Therapeutic Cargo	37
<i>Tek N. Lamichhane and Steven M. Jay</i>	
5 Delivery of Cytotoxic Mesenchymal Stem Cells with Biodegradable Scaffolds for Treatment of Postoperative Brain Cancer	49
<i>Kevin T. Sheets, Juli R. Bagó, and Shawn D. Hingtgen</i>	
6 Nanoparticles for Targeted Drug Delivery to Cancer Stem Cells and Tumor	59
<i>Hai Wang and Xiaoming He</i>	

PART II PASSIVE AND ACTIVE TARGETING METHODS

7 Exploiting Phage Display for Development of Novel Cellular Targeting Strategies	71
<i>William Marsh, Amanda Witten, and Sarah E. Stabenfeldt</i>	
8 CD44 Targeted Lipid Nanoparticles for MicroRNA Therapy	95
<i>Stephen L. Hayward and Srivatsan Kidambi</i>	
9 Ultrasound and Microbubble-Mediated Blood-Brain Barrier Disruption for Targeted Delivery of Therapeutics to the Brain	111
<i>Meaghan A. O'Reilly and Kullervo Hynynen</i>	
10 In Vitro Validation of Targeting and Comparison to Mathematical Modeling	121
<i>Jill M. Steinbach-Rankins and Michael R. Caplan</i>	

PART III MEASURING DELIVERY AND EFFICACY

11 Enzyme-Linked Immunosorbent Assay to Quantify Targeting Molecules on Nanoparticles 145
Rachel S. Riley, Jilian R. Melamed, and Emily S. Day

12 Tunable Collagen Microfluidic Platform to Study Nanoparticle Transport in the Tumor Microenvironment 159
Matthew R. DeWitt and M. Nichole Rylander

13 Utilizing the Lung as a Model to Study Nanoparticle-Based Drug Delivery Systems 179
Dylan K. McDaniel, Veronica M. Ringel-Scaia, Sheryl L. Coutermarsb-Ott, and Irving C. Allen

14 Non-Enzymatic Tissue Homogenization for Biodistribution Analysis 191
Danielle M. DiPerna, Alesia V. Prakapenka, Eugene P. Chung, and Rachael W. Sirianni

15 Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents 201
Allison N. Schorzman, Andrew T. Lucas, John R. Kagel, and William C. Zamboni

Index 229

Contributors

- IRVING C. ALLEN • *Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA; Graduate Program in Translational Biology, Medicine, and Health, Virginia Tech, Blacksburg, VA, USA; Department of Biomedical Sciences, Carilion School of Medicine, Virginia Tech, Roanoke, VA, USA*
- JULI R. BAGÓ • *Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*
- BAHAREH BEHKAM • *Department of Mechanical Engineering, Virginia Tech, Blacksburg, VA, USA; School of Biomedical Engineering and Sciences, Virginia Tech, Blacksburg, VA, USA; Macromolecules Innovation Institute, Virginia Tech, Blacksburg, VA, USA*
- MICHAEL R. CAPLAN • *School of Biological and Health Systems Engineering, Fulton Schools of Engineering, Arizona State University, Tempe, AZ, USA*
- EUGENE P. CHUNG • *Barrow Brain Tumor Research Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA*
- SHERYL L. COUTERMARSH-OTT • *Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA*
- EMILY S. DAY • *University of Delaware Biomedical Engineering, Newark, DE, USA*
- MATTHEW R. DEWITT • *Virginia Tech- Wake Forest School of Biomedical Engineering and Sciences, Blacksburg, VA, USA*
- DANIELLE M. DIPERNA • *Barrow Brain Tumor Research Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA*
- JACOB ELMER • *Department of Chemical Engineering, Villanova University, Villanova, PA, USA*
- STEPHEN L. HAYWARD • *Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE, USA; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA*
- XIAOMING HE • *Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA*
- SHAWN D. HINGTGEN • *Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Biomedical Research Imaging Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*
- KULLERVO HYNYNEN • *Physical Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada*

- STEVEN M. JAY • *Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA; Program in Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland, College Park, MD, USA; Program in Molecular and Cell Biology, University of Maryland, College Park, MD, USA*
- JOHN R. KAGEL • *Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab, UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*
- SRIVATSAN KIDAMBI • *Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; Nebraska Center for Integrated Biomolecular Communication, University of Nebraska, Lincoln, NE, USA; Nebraska Center for the Prevention of Obesity Diseases, University of Nebraska, Lincoln, NE, USA; Nebraska Center for Materials and Nanoscience, University of Nebraska, Lincoln, NE, USA; Mary and Dick Holland Regenerative Medicine Program, University of Nebraska Medical Center, Omaha, NE, USA*
- TEK N. LAMICHHANE • *Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA*
- ANDREW T. LUCAS • *Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab, UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*
- WILLIAM MARSH • *School of Biological and Health Systems Engineering, Ira A. Fulton Schools of Engineering, Arizona State University, Tempe, AZ, USA*
- DYLAN K. MCDANIEL • *Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA*
- JILIAN R. MELAMED • *University of Delaware Biomedical Engineering, Newark, DE, USA*
- MEAGHAN A. O'REILLY • *Physical Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada*
- TORAL R. PATEL • *Department of Neurological Surgery, UT Southwestern Medical Center, Dallas, TX, USA*
- THRIMOORTHY POTTA • *Chemical Engineering, School for Engineering of Matter, Transport and Energy, Arizona State University, Tempe, AZ, USA*
- ALESIA V. PRAKAPENKA • *Barrow Brain Tumor Research Center, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA; Department of Psychology, Arizona State University, Tempe, AZ, USA*
- KAUSHAL REGE • *Chemical Engineering, School for Engineering of Matter, Transport and Energy, Arizona State University, Tempe, AZ, USA*
- RACHEL S. RILEY • *University of Delaware Biomedical Engineering, Newark, DE, USA*
- VERONICA M. RINGEL-SCAIA • *Graduate Program in Translational Biology, Medicine, and Health, Virginia Tech, Blacksburg, VA, USA*
- M. NICHOLE RYLANDER • *Department of Mechanical Engineering, University of Texas at Austin, Austin, TX, USA; Department of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA*
- ALI SAHARI • *School of Biomedical Engineering and Sciences, Virginia Tech, Blacksburg, VA, USA*

- ALLISON N. SCHORZMAN • *Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab, UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*
- KEVIN T. SHEETS • *Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*
- RACHAEL W. SIRIANNI • *Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA; Barrow Neurological Institute, Phoenix, AZ, USA*
- SARAH E. STABENFELDT • *School of Biological and Health Systems Engineering, Ira A. Fulton Schools of Engineering, Arizona State University, Tempe, AZ, USA*
- JILL M. STEINBACH-RANKINS • *Department of Bioengineering and Center for Predictive Medicine, University of Louisville, Louisville, KY, USA*
- MAHAMA A. TRAORE • *Department of Mechanical Engineering, Virginia Tech, Blacksburg, VA, USA; School of Biomedical Engineering and Sciences, Virginia Tech, Blacksburg, VA, USA*
- HAI WANG • *Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA*
- AMANDA WITTEN • *School of Biological and Health Systems Engineering, Ira A. Fulton Schools of Engineering, Arizona State University, Tempe, AZ, USA*
- XINGWANG WU • *Department of Neurosurgery, Yale University, New Haven, CT, USA; Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China*
- WILLIAM C. ZAMBONI • *Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab, UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA*
- JIANGBING ZHOU • *Department of Neurosurgery, Yale University, New Haven, CT, USA*